CytoDyn Inc.

  • Home
  • About CytoDyn
    • Overview
    • Our Mission
  • Our Science
  • Pipeline
  • Our Team
    • Leadership Team
    • Scientific Advisory Board
    • Board of Directors
    • Join our Team
  • Publications & Posters
  • Newsroom
    • Press Releases
  • Investors
    • Overview
    • Investor FAQs
    • Investor Update Calls
    • Annual Meeting of Stockholders
    • Warrant Exercise Inquiries
    • Restricted Stock Inquiries
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • Investor FAQs
  • Investor Update Calls
  • Annual Meeting of Stockholders
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • News / Events
    • Overview
    • Press Releases
    • In The News
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Leadership Team
    • Presentations
    • Contacts
    • Company FAQs
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News / Events

  • Overview
  • Press Releases
  • In The News
  • IR Calendar
  • Email Alerts

CytoDyn Releases ESMO Breast Cancer Meeting Poster

May 15, 2025 8:30am EDT

CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors

May 13, 2025 8:30am EDT

CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer

May 06, 2025 8:30am EDT

CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany

Apr 29, 2025 8:30am EDT

March 2025 Letter to Shareholders

Mar 18, 2025 8:30am EDT

CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab

Feb 24, 2025 8:30am EST

CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories

Feb 06, 2025 8:30am EST

December 2024 Letter to Shareholders

Dec 17, 2024 8:30am EST

CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology

Nov 25, 2024 8:30am EST

CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial

Nov 04, 2024 8:30am EST
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
Next
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2025 CytoDyn Inc. All Rights Reserved.
Privacy Policy Legal Notice & Disclaimer Forward-Looking Statement Disclosure Sitemap